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Abstract: More than half of all known proteins, and almost all
membrane and extra-cellular proteins have oligosaccharide structures
or glycans attached to them. Defects in glycosylation pathways are
directly involved in at least 30 severe human diseases.
A multiple center cross-sectional study (China, Croatia, and Scot-
land) was carried out to investigate the possible association between
hypertension and IgG glycosylation. A hydrophilic interaction chroma-
tography of fluorescently labeled glycans was used to analyzeN-glycans
attached to IgG in plasma samples from a total of 4757 individuals of
Chinese Han, Croatian, and Scottish ethnicity.
Five glycans (IgG with digalactosylated glycans) significantly
differed in participants with prehypertension or hypertension compared
to those with normal blood pressure, while additional 17 glycan traits
were only significantly differed in participants with hypertension com-
pared to those of normal blood pressure. These glycans were also
significant correlated with systolic blood pressure (SBP) or diastolic
blood pressure (DBP).
The present study demonstrated for the 1st time an association
between hypertension and IgG glycome composition. These findings
suggest that the individual variation in N-glycosylation of IgG contrib-
utes to pathogenesis of hypertension, presumably via its effect on pro-
and/or anti-inflammatory pathways.
(Medicine 95(17):e3379)
Abbreviations: BMI = body mass index, DBP = diastolic blood
pressure, Fc = fragment crystallizable region, Ig =
immunoglobulin, IgG = immunoglobulin G, SBP = systolic blood
pressure.
INTRODUCTION
I n year 2000, 26.4% of the global adult population werediagnosed with hypertension (26.6% of men and 26.1% of
women), and 29.2% are estimated to have this condition by
2025 (29.0% of men and 29.5% of women), resulting in 972
million of affected adults in 2000 and estimation of 1.56 billion
affected by 2025.1 Hypertension ranks the 1st in chronic
medical problems in those who visited primary health care
providers in USA. According to The American Heart Associ-
ation, treatment of hypertension was estimated to cost both
directly and indirectly $76.6 billion in 2010.2
Incidence of hypertension rises with ageing, and it is
reported that 90% of middle-aged, and older adults are likely
to develop elevated blood pressure over their remaining life-
time.3 Hypertension is a complex disease that is influenced by
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both heritable and environmental factors. Genome wide associ-
ation studies have identified numerous common genetic var-
iants with small effects, as well as some rare genetic variants
with large effects on blood pressure,4 but the investigation of the
molecular genetics of hypertension still remains in its infancy.5
The examples of environmental factors influencing blood pres-
sure include: lifestyle factors such as dietary salt intake,6,7
consumption of fruits and low fat products, exercise,8 weight
loss,9 alcohol intake,10 caffeine consumption,11 and vitamin D
deficiency;12 early life events, such as low birth weight,
maternal smoking, and lack of breast feeding;13 and stress
factor, such as physical and psychological stress.14
Carbohydrates are important in many biological processes
including those underlying disease, and full significance of their
distribution and function is the focus of cutting edge research.
Glycosylation, which includes the addition of sugar chains to
proteins and lipids, is in fact the most common and complex
posttranslational modification.15 More than half of all known
proteins, and almost all membrane and extra-cellular proteins
have oligosaccharide structures or glycans attached to them.16
Defects in glycosylation pathways are directly involved in at least
30 severe human diseases, and complete absence of N-glycosyl-
ation is embryonically lethal.17 Glycosylation pathways are
altered in numerous diseases, giving rise to potential disease
markers and a better understanding of disease pathogenesis. In
autoimmune diseases, the glycosylation of serum antibodies
changes and in rheumatoid arthritis, for example, has been
correlated with disease progression and severity.18 Glycans were
also shown to havemultiple roles in the initiation and progression
of coronary artery disease, stroke, and peripheral vascular dis-
ease.19 Glycans are thus a key group of intermediate phenotypes
critical to many cell functions and therefore disease processes.
Immunoglobulin (Ig) is a cluster of proteins with antibody
activity (including IgA, IgD, IgE, immunoglobulin G [IgG],
IgM), accounting for approximately 20% of plasma proteins.
Among immunoglobulins, IgG is the most abundant (more than
80%), the major antibody in the secondary humoral response of
immunity.20 IgG exists in the form of a glycoprotein, with
average 2.8 N-linked sugar chains per molecule of IgG, 2 of
which are linked to the conservative region of fragment crystal-
lizable region (Fc) Asn297,18 and others are linked to the
nonconservative glycosylation sites of fragment antigen-bind-
ing (Fab) and the hinge region.21,22 Level and structure of IgG
glycosylation are associated with the incidence and develop-
ment of many inflammatory diseases, such as systemic
lupus erythematosus, glomerulonephritis, inflammatory bowel
disease, Alzheimer disease, and progressive mild cognitive
impairment.18,23–27 Kaneshige (1987)28 investigated IgG gly-
cosylation of 35 patients with type II diabetes and 14 cases of
age-matched healthy controls and found that IgG glycosylation
level is elevated in patients with diabetes. Pucic´ et al (2011)29
carried out the 1st population study of IgG glycome, showing
that there is a very high variability in the composition of the IgG
glycome. In a large-scale association study, Nikolac Perkovic
et al30 reported the association of body mass index (BMI) and
changes in IgG galactosylation, suggesting the relation of IgG
galactosylation with chronic inflammation that accompanies the
development of obesity.
Since hypertension is a worldwide public health problem
which is identified as the leading cause of cardiovascular
mortality by the World Health Organization, the present study
aimed to determine to what extent the IgG N-glycome correlates
with the occurrence of prehypertension and hypertension.
Recently, we reported associations between plasma glycans
and blood pressures in both Chinese and Croatian populations.31
In this study, we focused on IgG glycans to eliminate the effects
of varying concentrations of plasma proteins, which might
complicate the interpretation of the changes observed in the
total plasma glycome.
MATERIALS AND METHODS
Study Design
In order to determine to whether and what extent the IgG
N-glycome correlates with the occurrence of prehypertension
and hypertension, we carried out a population-based cross-
sectional study in Chinese, Croatian, and Scottish.
Participants and Settings
Chinese Han participants were recruited from a com-
munity-based cohort in Xicheng District, Beijing, from January
to April of 2012. All of the participants had to meet the
following inclusion criteria: over 18 years of age, no history
of somatic and psychiatric abnormalities as registered in their
medical records, and no history of taking any medicine in the
past 2 weeks. Individuals with a diagnosis of specific severe
diseases concerning the cardiovascular system, respiratory
system, genitourinary system, digestive system, and hematic
system were excluded.
Examinees from the Croatia and Scotland were recruited
within a large genetic epidemiology program32–34 on 2 Croatian
Adriatic islands Korcˇula and Vis, and the Northern Scottish
Orkney Islands.35 Sampling of the subjects from Croatia was
based on the information from the voting register of Croatia, and
adult inhabitants were included in the program.
Volunteers from the Northern Scottish Orkney Islands
were recruited within the Orkney Complex Disease Study.35
The sample recruiting protocols were described in details in the
previous publications.32–35
In total, 4757 participants, including 913 Chinese Han
from Beijing, 985 Croatian Korcˇula and 896 Croatian Vis, and
1963 Scottish Orkney were covered in the study.
The studies were approved by the local Ethics Committees
in China, Croatia, and Scotland, respectively. Written informed
consent was obtained from all participants. All studies have
been executed with the full cooperation of examinees, adequate
understanding, and have therefore been performed in accord-
ance with the ethical standards laid down in the 1964 Declara-
tion of Helsinki.
Variables
After participants filled in the questionnaire regarding their
demographic characteristics (gender and age), the physical
examinations and interview were carried out by trained nurses
and physicians. Systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured twice on the right arm by
trained nurses using a standard mercury sphygmomanometer
with the subjects resting at least 5minutes in a sitting position.
Hypertension and prehypertension were defined according to
the recommendations of the Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure.36 The classification
of BP for adults aged 18 years or older is as follows: normal,
SDP lower than 120mmHg, DBP lower than 80mmHg; pre-
hypertension, SDP 120 to 139mmHg, DBP 80 to 89mmHg;
stage 1 of hypertension, SDP 140 to 159mmHg, DBP 90 to
99mmHg; and stage 2 of hypertension, SDP 160mmHg or
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greater, DBP 100mmHg or greater. In this study, we combined
the stage 1 and stage 2 of hypertension in the final analysis.
Fasting blood samples were collected in the morning after
an overnight fasting by venipuncture for laboratory measure-
ments and glycomic analysis. The samples were processed
immediately and blood plasma was separated from whole blood
to be stored at 80 8C until further analysis.
IgG Isolation and Glycans Analysis
Glycan release and labeling of IgG of Chinese and Orkney
samples were done by reference to the ‘‘in solution’’ method as
described by Ruhaak et al.37 In short, IgG was denatured by
incubation with 20mL of 2% SDS at 60 8C for 10minutes.
Subsequently, 10mL 4% NP-40 and 1.25mU of N-glycosidase
F (ProZvme) in 10mL 5 PBS were added to the samples
and incubated overnight at 37 8C. Glycans were labeled with
2-aminobenzamide using 2-picoline-borane as reductant.
Labeled glycans were purified with hydrophilic interaction
liquid chromatography solid phase extraction using microcrys-
talline cellulose.38
Glycan release and labeling of Vis and Korcˇula samples
were performed by the ‘‘in gel’’ method as reported by Royle
et al.39 Briefly, IgG was immobilized in a block of sodium
dodecyl sulfate-polyacrylamide gel in a 96-well microtiter plate,
and N-glycans were released by digestion with recombinant N-
glycosidase F (ProZyme, San Leandro, CA). Released glycans
were labeled with 2-aminobenzamide and purified using solid-
phase extraction with Whatman 3MM chromatography paper.
IgG N-glycans were separated by hydrophilic interaction
liquid chromatography on a Waters Acquity UPLC instrument
(Walters Corporation, Milford, MA) into 24 peaks.40
Statistical Analysis
Based on our previously publication, in which plasma N-
Glycan G0 is associated with SBP in Chinese Han and Croatian
populations (r¼ 0.194 and 0.314, respectively),31 the sample
size of each group was estimated to be 538 using StatsToDo
(http://www.statstodo.com/SSizCorr_Pgm.php) at the signifi-
cance level of 0.05/23/2 and power of 90%.
UPLC measured glycans are subject to high experimental
variability that results in nonbiological, technical variability in
data. One part of technical variability comes from the global
properties of measurements which can be controlled with
normalization method to adjust individual measurements, bal-
ance them across all samples, and make them comparable. Raw
glycan intensities were therefore normalized by total area, that
is, peak area of every glycan in each sample was divided by the
total chromatographic area of the sample. Resulting glycan
values were percentages of a whole and all glycans of every
sample sum to a 100.
Samples were analyzed on 96-well plates, which made that
each cohort was run in 10 or more batches. Batch correction was
performed by applying empirical Bayes method ComBat with
parametric priors41 from ‘‘sva’’ R package42 to control the batch
effect, a source of nonbiological variability in the data. Model
matrix was created without covariates, and batch variable
presenting membership to 96-well plate was passed as a sep-
arate argument (batch argument in ComBat function). Prior to
batch correction, each glycan was log-transformed to account
for right-skewness of glycan distributions.
Both Croatian and Orkney ethnic groups are cohorts of
genetically isolated populations. Even though such populations
are homogeneous and lack population substructure, they are
well known for a larger proportion of related individuals,
resulting in inflated type I error in association studies.43 Indi-
vidual genotype data were obtained from larger genetic epide-
miology programs (Croatia – 10001 Dalmatians,34 Orkney -
Orkney Complex Disease Study),35 and quality control was
performed as described in Lauc et al 2013.44 To account for
family relatedness in the data, environmental residuals from
polygenic function of GenABEL package for R45 were com-
puted on batch corrected glycans. Polygenic function was
adjusted for relatedness in phenotypes by modeling polygenic
relationship (estimated from kinship matrix) between individ-
uals as a random effect. Residuals from this analysis were
corrected for relatedness and were used for association analyses
with blood pressure variables. Because of the lack of family
relationships in China cohort, this population was only cor-
rected for batch effects.
From 23 directly measured glycans an additional 54
derived traits describing the percentage of galactosylation,
sialylation, bisecting N-GlcNAc, and fucosylation were calcu-
lated (Supplementary Table S6, http://links.lww.com/MD/
A909). Since correction for relatedness was based on genotypes
of individuals, samples that were not genotyped were removed
prior to any statistical analysis. In total, 4102 individuals were
both successfully genotyped and had their glycans analyzed,
including 589 in Chinese, 829 in Korcˇula, 799 in Vis, and 1885
in Orkney. Prior to statistical analyses, all glycans were then
standardized to mean 0 and standard deviation of 1.
Participants with complete data of blood pressures and IgG
N-glycans were then selected for the analysis of descriptive
statistics, Mann–Whitney U test and bivariate correlation coef-
ficients. From this subset we selected participants with complete
information on gender and age for analysis of partial correlation
and multiple linear regression (1 person was excluded from the
Chinese population, which is showed in Supplementary Figure
S1, http://links.lww.com/MD/A910).
Normality distributions of all analysis results were tested by
the Kolmogorov–Smirnov test, and of which P< 0.10 was
considered statistically significant. For majority of the variables
that could not be assumed to be normally distributed (Table S1,
http://links.lww.com/MD/A904), median together with 25th per-
centile and 75th percentile were used in descriptive statistics, and
Mann–Whitney U test was used to test the differences between
groups.Multiple linear regressionwas applied to test associations
between glycans and blood pressures adjusted for gender and age.
Bivariate correlation coefficients of IgG N-glycans and blood
pressures were assessed by Spearman rank correlation method,
and partial correlation coefficients were also calculated to adjust
for gender and age. Pooling analysis was carried out by introdu-
cing dummy variables representing the different populations. All
reported P values were 2-sided, and P< 0.05 was considered
statistically significant (if not otherwise stated). Bonferroni cor-
rection in multiple comparisons was referred to our previous
publication,30,44 in which the significance level was divided by
the 23 (number of directly measured glycans) instead of 77 (total
of 23 directly measured and 54 glycans derived traits). Statistical
analyses were done with the SPSS software, version 13.0 (SPSS
Inc., Chicago, IL) and R version 3.1.0.46
RESULTS
Demographic and Biochemical Characteristics
Comparisons Among the Normal Blood Pressure,
Prehypertension, and Hypertension
Among the 4757 participants, 589 (64.5% of 913) Chinese
Han, 829 (84.2% of 985) Croatian Korcˇula, 799 (89.2% of 896)
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Croatian Vis, and 1885 (96.0% of 1963) from Scottish Orkney
had complete data on blood pressures and glycan levels, and
were included in the further analyses. We further excluded 2
participants from Orkney because of low blood pressures
(SDP< 90mmHg and DBP< 60mmHg). In total, 4100
samples were included in the final statistical analysis (see
Supplementary Figure S1, http://links.lww.com/MD/A910).
The gender and age distributions and the incidence of
hypertension of the 4100 participants are listed in Table 1. The
incidences of hypertension were 23.9%, 47.6%, 46.2%, and
29.6% in the recruited Chinese Han, Croatian Korcˇula and Vis,
and Scottish Orkney, respectively.
The IgG N-Glycome Composition in Individuals
With Normal Blood Pressure, Prehypertension,
and Hypertension
The results from descriptive analysis are listed in Supple-
mentary Table S2, http://links.lww.com/MD/A905, showing
the median together with 25th and 75th percentile of individual
IgGN-glycan traits by populations and blood pressures category
(normal, prehypertension, or hypertension). The comparisons of
IgG N-glycans between participants with hypertension, prehy-
pertension, or normal blood pressure in each population and the
pooling of 4 populations are shown in Table S3, http://
links.lww.com/MD/A906 (prehypertension vs normal) and
Table S4, http://links.lww.com/MD/A907 (hypertension vs nor-
mal), and part of those in the pooling of 4 populations (remain-
ing statistically significant after controlling for age and gender)
are summarized in Table 2. The corrected significance level was
set to 1.09 10–3, that is, the significance level 0.05 was
divided by 2 (prehypertension vs normal, and hypertension
vs normal), and then by 23 (number of direct measured IgG
N-glycan traits), referred to our previous publications.30,44
In comparisons between participants with prehypertension
and normal blood pressures, all of IgG N-glycans were not of
statistical significances in each individual population, although
G2n was lower in participant with prehypertension than those
with normal blood pressure in each populations after controlling
for age and gender (P¼ 0.1891, 0.0248, 0.2632, and 0.0113 in
Chinese, Korcˇula, Vis, and Orkney population, respectively)
(Figure 1, and Table S3, http://links.lww.com/MD/A906).
Therefore, the pooling analysis of the 4 populations was
performed. Five glycans were of significant differences in
participants with prehypertension compared to those of normal
in the pooling of the 4 populations, after controlling for age and
sex (P¼ 1.15E-04, 4.25E-04, 4.63E-04, 3.45E-04, and 3.33E-
04 for G2n, GP12, GP14, GP12n, and GP14n, respectively)
(Table 2). Although not of statistical significances in each
individual population, the sign of all coefficients are consistent
in each individual population and the pooling.
After controlling for age and sex, 22 of 77 IgG N-glycan
traits were significantly different between participants with
hypertension and those of normal blood pressure in the pooling
of the 4 populations, after controlling for age and sex (Table 2).
Thirteen, 2, and 5 statistically significant correlations were also
observed in Korcˇula, Vis, and Orkney populations, but not in
Chinese, after controlling for age and sex (Supplementary Table
S4, http://links.lww.com/MD/A907). Majority of glycans with
no statistical significances had the same directions in compari-
sons of each population with those in the pooling, except for
FG2S2/(FG2þFG2S1þFG2S2) and FBStotal/FStotal (Table S4,
http://links.lww.com/MD/A907). The level of FG2S2/
(FG2þ FG2S1þFG2S2) was statistically the same (b¼ 0.00,TA
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P¼ 1.00) in participants with hypertension or normal in Chi-
nese population, whereas it was higher in those with hyperten-
sion than in those of normal blood pressures in other 3
populations and the pooling of the 4 populations (b¼ 0.1762,
P¼ 0.0022; b¼ 0.0966, P¼ 0.0879; b¼ 0.1278, P¼ 7.33E-04;
b¼ 0.1060, P¼ 1.96E-05 in Korcˇula, Vis, and Orkney popu-
lations, respectively), might accounting for the ethnic difference
between Chinese and European (Table S4, http://links.lww.
com/MD/A907). The level of FBStotal/FStotal was lower in
participants with hypertension than those of normal blood
pressures in Chinese and Vis populations (b¼0.0084,
P¼ 0.8768 and b¼0.0231, P¼ 0.6715 in Chinese and Vis
populations, respectively), while higher in Korcˇula and Orkney
populations, with no statistical significance in all the compari-
sons (b¼ 0.1730, P¼ 1.98E-03 and b¼ 0.0856, P¼ 0.0102 in
Korcˇula and Orkney populations, respectively), might accord-
ing for the limited samples (Table S4, http://links.lww.com/
MD/A907).
TABLE 2. IgG N-Glycans Associated With Prehypertension or Hypertension in the Pooling of 4 Populations
Prehypertension Vs Normal Hypertension Vs Normal
IgG N-Glycans r P

r P

GP4 0.0825 0.0136 0.1109 3.28E-07
GP6 0.0490 0.1340 0.0766 4.20E-04
GP12 0.1528 4.25E-04 0.1283 4.32E-07
GP13 0.1216 0.0033 0.1105 1.26E-05
GP14 0.1140 4.63E-04 0.1252 4.18E-10
GP15 0.1274 1.66E-03 0.1338 2.65E-08
GP18 0.0985 5.20E-03 0.1076 3.57E-07
FGS/(FþFGþFGS) 0.0738 0.0474 0.0873 1.14E-04
FG2S2/(FG2þFG2S1þFG2S2) 0.0911 0.0227 0.1060 1.96E-05
FBG2S2/(FBG2þFBG2S1þ FBG2S2) 0.0611 0.1431 0.0924 2.50E-04
FtotalS1/FtotalS2 0.0783 0.0637 0.1164 8.10E-07
FS1/FS2 0.0795 0.0661 0.1151 4.51E-06
FBStotal/FStotal 0.0436 0.2188 0.0802 5.43E-04
GP4n 0.0946 4.97E-03 0.1218 1.69E-08
GP6n 0.0546 0.0974 0.0788 2.92E-04
GP12n 0.1543 3.45E-04 0.1299 2.67E-07
GP13n 0.1230 2.26E-03 0.1109 8.62E-06
GP14n 0.1175 3.33E-04 0.1231 7.90E-10
GP15n 0.1253 1.50E-03 0.1307 3.42E-08
G0n 0.0865 7.43E-03 0.1169 2.14E-08
G2n 0.1286 1.15E-04 0.1331 5.76E-11
Bn/(FnþFBn) 0.1255 1.92E-03 0.1122 7.24E-06
IgG¼ immunoglobulin G.
Bold in P-value represent P< 1.09E-03 (corrected significance level).
FIGURE 1. The boxplot of G2n in participants with normal, prehypertension, and hypertension.
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The Correlations of IgG N-Glycan Traits and
Systolic or Diastolic Blood Pressures
The correlations of IgG N-glycan traits and SBP or DBP in
each population and the pooling of the 4 populations are shown
in Table S5, http://links.lww.com/MD/A908, and those of
statistical significance are summarized in Table 3 (SBP) and
Table 4 (DBP), with corrected significance level of 1.09E-03
(the significance level 0.05 was divided by 2 [SBP and DBP],
and then by 23 [number of direct measured IgG N-glycan
traits]).
In the pooling analysis of 4099 individuals, 25 IgG
N-glycan traits were correlated (10 positively and 15 nega-
tively) with SBP after adjustment for sex and age, among
which 10 were of significance in Korcˇula population, 18 in
Orkney population, and there was no significant correlations
in the other 2 populations (Table 3). The biggest coefficient
was observed for GP12n (b¼ 0.0932, P¼ 2.64E-09). Even
though not all of them were statistically significant, all
but FBS1/(FS1þFBS1) showed the same trend, suggesting
that more samples are needed in each cohort to reach the
statistical power. This was further hinted by results of the
pooled analysis.
Nineteen IgG N-glycans trait were correlated (6 positively
and 13 negatively) with DBP after adjustment for sex and age in
the pooling (Table 4), with the biggest coefficients in G2n
(b¼ 0.0824, P¼ 1.43E-07). Similarly, although only 8 and 2
of 19 coefficients remained significant in Korcˇula and Orkney
population but not in other 2 populations, the trends of all
correlation coefficients in pooling analysis were the same as
those in the analysis of each individual population.
DISCUSSION
Given the prevalence of hypertension in Chinese Han,
Croatian’s Vis and Korcˇula, and Scottish Orkney cohorts
(23.9%, 47.6%, 46.2%, and 29.6 %, respectively), hypertension
continues to be a major health problem in the investigated
populations, and identification of biomarkers that might trans-
late new knowledge into prevention and treatment of hyperten-
sion is a pressing need. The differences in prevalence of
hypertension among different populations might be caused
by the differences in age distribution (the median age [inter-
quartile range] were 46 [41–50], 57 [47–67], 57 [45–69], and
54 [41–65] in Chinese Han, Croatian Korcˇula and Vis, and
Scottish Orkney, respectively). In addition, the genetic isolation
of the Croatian Korcˇula and Vis could be the genetic factor
contributing to the observed difference of incidence of BP
among these different populations.
Glycans have been reported to be associated with several
diseases, such as systemic lupus erythematosus, glomerulone-
phritis, inflammatory bowel disease, Alzheimer disease, and
progressive mild cognitive impairment.18,23–27 Based on a
combination of approaches of a cross-sectional survey at popu-
lation level and an association study at glycomic level, this
multiple centers’ study aimed to examine a possible association
between hypertension and IgG glycosylation. The present study
is the 1st such example based on a large-scale population-based
study that demonstrates a possible association between blood
pressures and IgG glycosylation in both Asian and Europeans.
The results showed that 5 IgG glycosylation traits (G2n,
GP12, GP14, GP12n, and GP14n) are strongly and statistically
significantly associated with both prehypertension and hyper-
tension. Other 17 glycan traits (GP4, GP6, GP13, GP15,
GP18, GP4n, GP6n, GP13n, GP15n, FGS/[FþFGþFGS],
FG2S2/[FG2þFG2S1þFG2S2], FBG2S2/[FBG2þFBG2S1þ
FBG2S2], FtotalS1/FtotalS2, FS1/FS2, FBStotal/FStotal, G0n, and
Bn/[Fnþ FBn]) are significantly associated only with hyperten-
sion. It should be noted that association of these traits with
prehypertension, while insignificant after stringent multiple
testing correction we used, is in many cases marginally sig-
nificant, and exhibited consistent sign of association, albeit the
correlations were weaker (Table 2). Furthermore, 25 glycan
traits are correlated with SBP (Table 3), while 19 glycan traits
are also correlated with DBP (Table 4). Although analysis of
individual populations does not reveal statistical significance,
the pooled analysis does, and the effect estimates are very
consistent – in terms of sign and the magnitude – across
populations (Tables 3 and 4). The main issue here is that
hypertension strongly associates with age, and since IgG gly-
cans are also highly associated with both chronological and
biological ages, the correction for chronological age is remov-
ing a significant part of associations between glycans and
biological age.47
The same concerns other glycan traits: although not stat-
istically significant, we see strong enrichment of low P-values
in comparison of normal versus prehypertension group (e.g., 19
of 77 P-values are <0.05, with null expectation of P< 1E-4,
exact binomial P< 1E-8). The results from our previous study
suggested that N-glycosylation of plasma proteins is affected by
both age and sex, and that changes in the levels of glycan
features can be associated with metabolic syndrome com-
ponents including BMI, SBP, DBP, and fasting plasma glucose
simultaneously.31 The present data suggested that blood press-
ures are associated with individual variation in the extent of
fucosylation, the degree of branching, levels of sialylation, and
levels of glycosylation. Individual variation in IgG glycome
composition is very high.29 Despite the absence of a direct
genetic template for individual glycans, their levels are up to
80% heritable48 and associate with different genetic44 and
epigenetic loci.48
Ebringer and Doyle (1970)49 reported that serum IgG
levels are significantly higher in 118 severely hypertensive
patients compared with a group of 163 normotensive blood
donors, suggesting that the raised levels of serum IgG may be
an index of vascular damage induced by hypertension. Ohara
et al (2014)50 reported that urinary excretion of IgG is signifi-
cantly elevated in nondiabetic hypertension patients compared
to the healthy controls and in type 2 diabetic patients with
hypertension compared to those with type II diabetes only.
Also, serum IgG antibodies to Chlamydia pneumoniae were
reported to be associated with essential hypertension in a
highly homogeneous population from Majorca, Balearic
Islands, Spain.51 The present study showed that the quantitat-
ive changes of IgG glycosylation are associated with hyper-
tension, besides the level of IgG.
Alterations of the immune response have been implicated
in the pathogenesis of hypertension for more than 5 decades.
White and Grollman (1964)52 reported that immunosuppression
attenuates hypertension in rats with partial renal infarction.
Guzik et al (2007)53 found that the degree of hypertension
caused by chronic angiotensin II infusion is markedly blunted in
RAG-1/ mice, which lack both T and B cells. Marvar et al
(2010)54 further found that T cells are essential for the devel-
opment of deoxycorticosterone acetate-salt and norepinephrine-
induced hypertension, suggesting that hypertension has been
involved in both central and peripheral mechanisms of T-
lymphocyte activation and vascular inflammation produced
by angiotensin II-induced hypertension. Through examination
Wang et al Medicine  Volume 95, Number 17, April 2016
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on hypertensive response of mice that have severe combined
immunodeficiency, Crowley et al (2008)55 showed that T cells
are essential for the development of the angiotension II induced
hypertension and immunoefficiency can lead to decreased left
ventricular hypertrophy, cardiac fibrosis, and albuminuria fol-
lowing angiotension II administration. Several studies showed
that cytokines produced by T cells and other inflammatory cells
contribute to hypertension.56–59
Recently, Harrison et al (2011)60 reviewed the relation
between inflammation, immunity, and hypertension, and pro-
posed that hypertensive stimuli (such as angiotension II and
salt) cause a modest elevation in blood pressure (prehyperten-
sion), then lead to neoantigen formation, promoting cell
activation and entering kidney and vasculature, and then
T cells-derived signals such as IL-17 promote entry of other
inflammatory cells such as macrophages releasing cytokines
that cause vasoconstriction and promote sodium and water
absorption, and ultimately start severe hypertension. Further-
more, based on the evidences from both basic and clinical
studies, Montecucco et al (2011)61 proposed the possible direct
role of inflammation in the pathophysiology of essential hy-
pertension. Our findings that the level of IgG galactosylation
(G2n, the percentage of digalactosylated structures in total
neutral IgG glycans; GP12, GP14, GP12n, and GP14n, all with
digalactosylation structure) are significantly lower in the
participants with prehypertension, suggesting that IgG galac-
tosylation might occur at the early stage of pathogenesis of
hypertension, and play role in the development of severe
hypertension from prehypertension.
Glycosylation of the IgG, Fc-, or Fab-fragments has a role
in enhancing or blocking the pro- and anti-inflammatory effec-
tor functions.62 IgGmediates pro- and anti-inflammatory activi-
ties mainly through the engagement of its constant region (Fc
part) with distinct Fcg receptors. The differential compositions
of the N-glycans determine the effector functions by altering the
affinity of IgG to activating or inhibitory FcgRs.63 A recent
study showed that highly galactosylated IgG1 mediates anti-
inflammatory activity by facilitating the association of the
inhibitory receptor FcgRIIB and a C-type lectin-like receptor
dectin-1.64 In addition, the lack of core fucosylation of anti-
HPA-1a–specific IgG1 also dramatically increases the binding
affinity to FcgRIIIa and FcgRIIIb but not FcgRIIa.65 The
findings of the association between hypertension and the num-
ber of terminal galactose in IgG (e.g., glycan without galactose
[GP4, GP4n, GP4, GP6n, and G0n] increases, while glycans with
galactose [GP12, GP13, GP14, GP15, GP18, GP12n, GP13n,
GP14n,GP15n, and G2n] decreases from normal to hypertension,
and also the similar pattern of glycans correlation with SBP or
DBP, or the core fucosylation or bisecting GlcNAc of IgG, e.g.,
GP14, GP14n, and Bn/(Fnþ FBn) decreases successively from
normal to hypertension, and negatively correlates with SBP or
DBP) corresponds to the alteration of the affinity of IgG to
activating or inhibitory FcgRs, and suggests that galactosylation
or core fucosylation of IgG contribute to the increase of blood
pressure via inflammatory signaling.
IgG also acquires anti-inflammatory properties depending
on Fc sialylation. This differential sialylation may provide a
switch from innate anti-inflammatory activity in the steady
state to generate adaptive pro-inflammatory effects upon anti-
genic challenge.66 Sialylation of IgG exerts anti-inflammatory
effects,67 through interactions with the lectin receptor specific
intercellular adhesion molecule-3-grabbing nonintegrin-
related-1 or dendritic cell-specific intercellular adhesion
molecule-3-grabbing non-integrin.68 IgG with disialylation
(FG2S2/[FG2þFG2S1þFG2S2] and FBG2S2/[FBG2þ
FBG2S1þ FBG2S2]) increases with hypertension, while other
IgG sialylation (GP18, FGS/[FþFGþFGS], FtotalS1/FtotalS2,
and FS1/FS2) decreases with hypertension, suggesting that
sialylation is associated with hypertension via decreasing
adaptive pro-inflammatory effects of IgG. This is further
supported by the observation of the opposite associations:
positive correlation of SBP with FG2S2/(FG2þFG2S1þ
FG2S2) and FBG2S1/(FBG2þ FBG2S1þFBG2S2), but
negative with GP18, FtotalS1/FtotalS2, and FS1/FS2.
The strength of this study is that it is the 1st population-
based study on the association of IgG N-glycosylation and
hypertension, and we found that the N-glycome profile is
differed between the normal, hypertension, and hypertension.
However, several limitations must be considered when inter-
preting these findings. First, the present study is a cross-sec-
tional study, thus it cannot judge whether IgG N-glycosylation
changes are causal for hypertension or just parallel with hyper-
tension. Second, hypertension is diagnosed only after at least 2
separate visits to a clinic, whereas we used a single measure-
ment in this multiple ethnic cross-sectional study. Thirdly, no
other risk factors (such as BMI, smoking, diabetes, etc.) were
controlled in this study. The absence of controlling for potential
risk factors may confound the association, but at certain extend
the consistent results among populations investigated with
different ethnic background might help this study to profile
objectively the association observed between IgG glycosylation
and hypertension.
In conclusion, the present study showed that galactosyla-
tion of IgG is moderately associated with prehypertension and
hypertension, while certain types of IgG N-glycan traits (sia-
lylation, core fucosylation, and bisectingN-GlcNAc) are associ-
ated with hypertension, but not prehypertension. Sialylation,
bisecting N-GlcNAc, galactosylation, and core fucosylation of
IgG are also associated with SBP or DBP. Considering that
galactosylation, sialylation, and core fucosylation of IgG
involve directly in inflammation pathways, and inflammation
plays a direct role in the pathophysiology of essential hyper-
tension, our findings suggested that individual variation of
N-glycosylation of IgG might contribute to hypertension via
its effects on pro- and anti-inflammation pathways.
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